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Abstract
Background: Many different preventatives have showed efficacy in the treatment of migraine. National guidelines
differ in their recommendations and patients’ characteristics are usually taken into account in their selection. In
Spain, real life use of preventive therapies seems to be heterogeneous. We aimed to evaluate differences in clinical
practice and adherence to national guidelines among Spanish neurologists.
Methods: Observational descriptive study. A survey was conducted among neurologists ascribed to the Spanish
Society of Neurology. Participants were differentiated in accordance with their dedication to headache disorders.
We analysed socio-demographic parameters and evaluated 43 questions considering migraine management as well
as therapeutic choices regarding migraine sub-types and finally, neurologists’ personal perception.
Results: One hundred fifty-five neurologists participated from 17 different regions, 43.4% of them female and 53.3%
under 40 years of age. 34.9% confirmed headache disorders as their main interest.
The first choice for preventive therapy in chronic migraine among participants was topiramate (57%) followed
by amytriptiline (17.9%) and beta-blockers (14.6%). However in episodic migraine, the preferred options were
beta-blockers (47.7%), topiramate (21.5%) and amytriptiline (13.4%). Regarding perceived efficacy, topiramate
was considered the best option in chronic migraine (42.7%) followed by onabotulinumtoxinA (25.5%) and
amitryptiline (22.4%). Where episodic migraine was concerned, surveyed neurologists perceived topiramate (43.7%) and
beta-blockers (30.3%) as the best options. When we evaluated the duration of treatment use with a view to adequate
therapeutic response, 43.5% of neurologists preferred 3 months duration and 39.5% were in favour of 6
months duration in episodic migraine. However, considering the preferred duration of treatment use in
chronic migraine, 20.4% recommended 3 months, 42.1% preferred 6 months and 12.5% and 22.4% opted
for 9 and 12 months respectively. When considering onabotulinumtoxinA therapy, the number of prior
therapeutic failures was zero in 7.2% of neurologists, one in 5.9%, two in 44.1%, three in 30.9% and four
or more in 11.9%. Following an initial treatment failure with onabotulinumtoxinA, 49% of subjects decided against a second
treatment. The number of OnabotA procedures before considering it as ineffective was two in 18.9% of neurologists, three
in 70.8% and four in 10.4%.
Conclusions: The initial management of migraine among Spanish Neurologists is in line with most guidelines, where first
choice preventative drugs are concerned. The Management of episodic migraine differed from chronic migraine, both in
terms of neurologist preference and in their perceived efficacy.
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Introduction
Headache is the most frequent reason for referral to out-
patient neurology offices in Spain [1]. Headache is a
common presenting complaint in neurology, migrai-
neurs being the most common subgroup in the out-
patient setting [2]. The Spanish Society of Neurology
periodically publishes guidelines on the main neuro-
logical conditions, in order to help clinicians in their
daily practice.
The Spanish Headache Study Group guidelines [3] rec-
ommended topiramate and beta-blockers as the first
choice of preventive therapy in Episodic Migraine,
followed by flunarizine, Lisinopril and candesartan. Val-
proic acid is recommended only in a tertiary referral
centre and is currently contraindicated in women of
childbearing age [4]. On the other hand, the first oral
preventive option in Chronic Migraine is topiramate,
followed by amitriptyline and in a third level flunarizine
and beta-blockers.
Despite the high number of therapies available, some
of them have not been properly studied and the evidence
is based on experts’ opinions [5]. The arrival of new
drugs to our armamentarium should improve the care of
migraine patients [6, 7]. Understanding the needs of cli-
nicians may help in the development of new therapeutic
strategies and guidelines.
We aimed to evaluate the preferences in the manage-
ment of migraine with preventive therapies, the per-
ceived efficacy and safety of the current therapies among
Spanish Neurologists.
Material and methods
We conducted an observational, transversal study. The
studied population was the community of Spanish Neu-
rologists ascribed to the Spanish Society of Neurology.
The study included an anonymous survey mailed three
times to all neurologist members of the Society. It in-
cluded 8 questions about demography and 43 concern-
ing preventative preferences and utilization.
The survey analysis considered if the neurologist was a
member of the Spanish Headache Study Group (SHSG)
and those in whom headache disorders were their main
area of interest. For analytic purposes, we categorized re-
sponders in two differentiated age groups: junior neurol-
ogists if they were under 40 years old (juniors) and
senior neurologists if they were 40 years old or above
(seniors in advance). In Spain most trainees complete
their Neurology training at age 29 following 4 years of
residency.
Demographic variables were gender, age group, region
of origin, main area of interest, adscription to the SHSG,
and duration spent working in headache medicine.
Eligibilty criteria of treatments included all those men-
tioned in the Official Guidelines of the Spanish Headache
Study Group, namely: beta-blockers, amitriptiline, topira-
mate, valproic acid, zonisamide, lisinopril, candesartan,
fluoxetine, venlafaxine, desvenlafaxine, lamotrigine, mag-
nesium, flunarizine, riboflavine, pregabalin, onabotulinum-
toxinA (onabotA) and anaesthetic blockade of greater
occipital nerves (GON) [3]. We analysed drugs individu-
ally, including two specific questions about the percentage
of combined treatments in the first visit and in global.
We specifically evaluated which was the preferred
beta-blocker and we included among the possible answers
propranolol, nadolol, atenolol, bisoprolol, nebivolol and
esmolol. We analyzed by separate onabotA management
in terms of number of prior preventive failures, employed
units per procedure and long-term management.
Surveyed neurologists were asked about their pre-
ferred first and second choices in preventive therapy in
chronic migraine (CM), episodic migraine with aura
(EMWA), and in episodic migraine without aura
(EMOA). We also gave special consideration to condi-
tions such as depression or pregnancy.
Participants were also questioned about their personal
opinion regarding the most effective drugs in both
Chronic and Episodic Migraine and which they thought
were the best-tolerated drugs.
The Scientific Committee of the Spanish Society of
Neurology approved the study and all the participants
agreed to participate voluntarily.
We present data as number and percentage. Missing data
was managed by complete case analysis. We employed SPSS
v16.0 for the Statistical Analysis. For the comparison of
qualitative variables, we used Chi [2] test. In the comparison
of continuous variables with qualitative variables, the
employed test was Student t test and Median test in case of
non-normal distribution or < 30 variables per group. Correl-
ation between quantitative variables was analysed with Pear-
son test. We considered an alpha error value of 0.05.
Results
Demographic parameters
We received responses from 153 neurologists, among
which 53 (34.9%) were ascribed to the Spanish Headache
Study Group. The percentage of female participants was
43.4%. Age of participants was < 30 years in 11.8%, 30–
39 in 41.4%, 40–49 in 16.4% and > 50 in 30.4%.
The most frequent regions were Madrid, with 32 par-
ticipants (21.1%) and Catalonia with 24 (15.8%). The
time since they were focused on headache disorders was
< 6 years in 35.4%, 6–10 years in 14.6%, 11–15 years in
14.6%, 16–20 in 10.4% and > 20 years in 25%.
First choice drugs
First choice in chronic migraine
Topiramate was the first choice drug in 57% of re-
sponders, followed by amitriptyline (17.8%), beta-blockers
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(14.6%) and flunarizine (6%). The most frequent second
choice drug were beta-blockers (25.7%) followed by topir-
amate (23.2%), amitriptyline (20.5%), onabotA (10.6%) and
flunarizine (9.3%). Complete data on all possible drugs is
shown in the Additional file 1.
Management of CM seemed to be different among
general neurologists when compared with those focused
on headache disorders, particularly concerning the first
choice selection of topiramate (49.5% vs. 71.2%, p:0.017),
amitriptyline (23.2 vs. 7.7%, p:0.016) and flunarizine
(9.1% vs. 0%, p:0.027).
Comparison of juniors and seniors did not yield any
significant differences.
First choice in episodic migraine without aura
The preferred drugs were beta-blockers (47.7%),
followed by topiramate (21.5%), amitriptyline (13.4%)
and flunarizine (11.4%). The most frequent second
choice was topiramate (44.6%), followed by beta-blockers
(23.6%), amitriptyline (15.5%), flunarizine (9.5%) and
zonisamide (4.1%). Further data is available in Additional
file 1.
First choice in episodic migraine with aura
Topiramate was the first choice for 50.3% of partici-
pants, followed by beta-blockers (23.2%) amitriptyline
(9.3%), flunarizine (6.6%) and lamotrigine (2.6%). The
most frequent second choice was topiramate (31.8%),
beta-blockers (25.7%), lamotrigine (10.1%), amitriptyline
(9.5%), zonisamide (8.8%), flunarizine (6.8%) and valproic
acid (6.1%). Full list of responses are available in the
Additional file 1.
We did not find significant differences between head-
ache specialists and general neurologists concerning the
preferred drug in episodic migraine treatment, neither
with nor without aura.
Between junior and seniors, there was a trend but re-
sults did not reach statistical significance, to use less
topiramate among juniors (17.7% vs. 25.7%, p:0.1) and
flunarizine (8.9% vs. 14.3%, p:0.2) and higher use of ami-
triptyline (16.5% vs. 10.0%, p:0.2).
Figure 1 represents the pooled first and second choices
in Chronic Migraine (CM), Episodic Migraine with aura
(EMWA) and Episodic Migraine without aura (EMOA).
Management was described to be different when treat-
ing female patients in 76.3% of neurologists. The pre-
ferred option in case of pregnancy was beta-blockers in
57.7%, magnesium (17.3%), Greater Occipital Nerve
blockades (16.3%), onabotA (3.8%), lamotrigine (2.9%)
and others (2%). Valproic acid was avoided in female
migraineurs by 90.1% of responders.
In patients with depression, the preferred drugs were
amitriptyline in 67.1%, venlafaxin in 15.3%, and topira-
mate in 11.3%.
Responses about perception of efficacy
Chronic migraine
Topiramate was considered the most effective drug in
the treatment of CM by 42.7% of responders, followed
by onabotA in 25.2%, amiptriptyline (22.4%), beta-
blockers (3.5%) and flunarizine (2.1%).
The second most frequently considered drug was also
topiramate in 34.3%, followed by amitriptyline (19.7%),
beta-blockers (15.3%), onabotA (8%), venlafaxin (5.8%),
valproic acid and zonisamide (5.1% each). Full list of re-
sponses can be consulted in Additional file 1.
OnabotA was considered as the most effective drug
more frequently among neurologists with special interest
in headache disorders than in general neurologists (34%
vs. 18.2%, p:0.029). In the group of general neurologists,
amitryptiline tended to be considered as the most effect-
ive drug in more cases than in headache specialists
(27.3% vs. 9.4%, p:0.1). We did not found statistically sig-
nificant differences between junior and senior neurolo-
gists concerning preferences in terms of efficacy.
Fig. 1 First choice drugs in Chronic Migraine (CM) (blue), Episodic Migraine With Aura (EMWA) (red) and Episodic Migraine Without Aura (EMOA)
(green). Percentage shows the pooled percentage of people who responded each drug as first or second choice in each indication
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Episodic migraine
The drug perceived as most effective in episodic mi-
graine was topiramate (43.7%), followed by beta-blockers
(30.3%), amitriptyline (14.8%) and flunarizine (8.5%).
Beta-blockers were considered the second most effective
option in 32.9% of the answers, followed by topiramate
(28.6%), amitriptyline (17.1%) and flunarizine (11.4%).
Full data about efficacy can be consulted in Additional
file 1.
Preferences of neurologists with special interest of
headache did not differed from general neurologists,
only amitriptyline was described as less effective (17.6%
vs. 25.0%, but differences were not statistically significant
p:0,56).
We found differences in the perception of efficacy of
topiramate and amitriptyline comparing senior and jun-
ior neurologists. Seniors considered topiramate as the
most effective more often (54.5%vs34.2%, p:0,022),
whereas juniors considered amitriptyline as the most ef-
fective in more cases (21.1%vs7.6%, p:0,033).
The preferred beta-blocker among surveyed neurol-
ogists was propranolol (62.1%), followed by nadolol
and nebivolol (15.85% each), atenolol (4.1%) and
bisoprolol (2.1%).
Perceptions about tolerability
Drugs considered as best tolerated in a young patient
without any comorbidity were betablockers (42.4%),
followed by flunarizine (14.6%), onabotA (11.3%), topira-
mate and amitriptyline (9.3% each), and magnesium
(4%). Full data about tolerability preferences can be seen
in Additional file 1.
Figure 2 shows survey responses considering tolerabil-
ity, showing the percentage of neurologists that consid-
ered each drug as the best tolerated and the second best
tolerated respectively.
Differing opinions emerged between headache special-
ists and general neurologists where the best-tolerated
drugs were concerned, however these results were not
statistically significant Fig. 3.
In the correlation analysis we found that the correl-
ation between considering topiramate well tolerated and
selecting it as first choice in CM was r = 0,95, (p = 0,24,
Pearson test), in EMOA was r = 0,23 (p = 0,005) and in
EMWA r = 0,23 (p = 0,005); whereas the correlation be-
tween considering it as the most effective and selecting
it as first choice was higher, r = 0,46 in EMOA (r <
0,0001) and r = 0,43 in EMWA (p < 0,0001) and for CM
was r = 0,31 (p < 0,0001).
Management of patients
Participants described patients comorbidities as the most
important factor when choosing a preventative (70.2%)
followed by guidelines recommendations (13.9%), per-
sonal experience (11.3%) and patients’ preferences
(4.6%).
Regarding the management in primary care, 80.9% of
the surveyed neurologists considered that the general
practitioner should prescribe preventatives before refer-
ral to neurology office. The number of preventatives
considered to fail before referring the patient was none
in 4.6%, one in 13.8%, two in 56.6% and three or more
in 25% for episodic migraine whereas in chronic mi-
graine was none in 21.1%, one in 22.4%, two in 40.8%
and three or more in 15.8%.
Regarding the duration of preventive therapy until
achieved therapeutic response, in EM 51% of responders
affirmed to keep the treatment for 3 months or less
whereas in CM 42,1% treated during 6 months and
34,9% during at least 9 months. Figure 4 shows the dur-
ation of the treatment in EM or CM.
Polytherapy was only considered in selected cases in
the first visit by 22.3% of the participants. When asked
Fig. 2 Best tolerated drugs according to responders’ opinions. In light blue, percentage of responders that selected each drug as the best
tolerated. In light orange, percentage of responders that selected each drug as the second best tolerated. Number represents percentage
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about management in their patients, the percentage of
them treated with polytheraphy was estimated to be 0–
10% by 14.5% of neurologists, 11–25% in 44.1%; 26–50%
in 27.6%; 51–75% in 9.2% and > 76% in 4.6%.
OnabotulinumtoxinA management
Regarding specific OnabotA questions, we asked about
the number of failure (efficacy or tolerability) in oral
preventatives before starting OnabotA. Response was
none in 7.2% of neurologists, one in 5.9%, two in 44.1%,
three in 30.9%, four in 9.9% and five or more in 2%.
When asked whether they considered specifically the
failure to any preventative, 51.4% mentioned topiramate,
4.9% amitriptyline, 4.2% beta-blockers and 36,6% said
they did not consider any specific failure.
When comparing between headache specialists and
general neurologists, the former started OnabotA earlier
than general neurologists (p:0.014) Fig. 5.
We did not find differences when comparing juniors
and seniors and 54.3% affirmed to start OnabotA after
two preventive failures and 83,9% after the failure of
three preventive drugs (p:0.49).
Concerning OnabotA dose, in the first procedure,
50.9% of responders injected 155 Units and 41.7% 150 U.
Figure 6 shows the units used per procedure by the sur-
veyed neurologists. Following an initial treatment failure,
51% of responders increased the dose in the second pro-
cedure and in case of inefficacy, 83% of responders did
increased the dose from 155 units in the third
procedure.
The number of OnabotA procedures before consider-
ing it as ineffective was two in 18.9% of neurologists,
three in 70.8% and four in 10.4%.
Only 66 participants (38,2%) described to be assisted
by a nurse in the OnabotA preparation. The percentage
of clinicians that self-charged the medication was higher
Fig. 3 Opinions among surveyed neurologists about each drug tolerability. In orange: answers from Neurologists with special interest in
headache. In green: answers from general neurologists
Fig. 4 Optimal duration of preventative treatment according to surveyed
neurologists. Numbers represent the percentage of responders that
answered each duration. Orange bars represent episodic migraine; red bars
represent chronic migraine
Fig. 5 Number of oral preventative failures prior to the OnabotA
therapy. Numbers represent the percentage of responders that
affirmed to start OnabotA after the failure of each number of
therapeutic failures. In orange, answers from Headache Specialists;
Green, answers from general neurologists
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among headache specialists compared with general neu-
rologists (50.9 vs. 39.4%, p:0.008).
Figure 7 shows the percentage of patients in which re-
sponders affirmed to perform a reduction of OnabotA in
case of efficacy, trying to stop the therapy and Fig. 8
shows the percentage in which they were able to finally
stop it.
Discussion
First choice
The main findings of our study were that topiramate
was selected as the first choice drug in CM and EMWA
and the second choice in EMOA, whilst beta-blockers
were the drugs of choice in EMOA. These findings fol-
low the Spanish Headache Study Group recommenda-
tions [3], but differences were found in the second and
third choice, as few responders considered valproic acid
as a potential option and amitriptyline was selected be-
fore flunarizine in all three groups.
According to European Medicines Agency [4] recom-
mendations, subscribed by the European Headache Fed-
eration, valproic acid should be avoided in women in
childbearing age. In our sample, 90.1% of responders
followed that recommendation.
The percentage of responders that mentioned other
drugs such as candesartan [8], lisinopril [9], zonisamide
[10], lamotrigine [11] was around 10%, despite our
guidelines place some of them on a par with
amitriptyline.
Efficacy
Only topiramate and OnabotA have proved their efficacy
in randomized controlled trials in Chronic Migraine and
only recently its efficacy has been directly compared
[12]. Despite the different methodology of the studies,
number of headache days reduction in the pivotal trials
ranged from − 3,5 to − 6,4 for topiramate [13, 14]and −
7,8 to − 9 for OnabotA [15, 16]. Our findings suggest
that neurologists perceived Topiramate as more effective
Fig. 6 Percentage of participants that administer each defined number of OnabotA units per procedure. Light blue represents the first procedure,
dark blue the second procedure and purple the third procedure
Fig. 7 Discontinuation trial of OnabotA in case of efficacy:
percentage of cases in which responders try to discontinue OnaboA
in case of efficacy
Fig. 8 Successful discontinuation of OnabotA in case of efficacy:
percentage of cases in which responders succeed to discontinue
OnaboA in case of efficacy
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than OnabotA, both among headache specialists and
general neurologists. In the last group, perception about
OnabotA efficacy was even lower and amitriptyline was
chosen as more efficacious.
We also consider of interest how beta-blockers were
perceived, as they were considered as the second most
effective option in EM, slightly after topiramate. How-
ever, in Chronic Migraine, the percentage of neurologists
that considered them as the most effective option was
significantly lower, only 3.5% them in comparison with
30.3% in EM. Only one study compared them directly
and could not find statistically significant differences in
Episodic Migraine patients [17].
Another topic of discussion is the duration of the pre-
ventive treatment. Spanish guidelines recommend at
least 6 months of treatment [3], but we found a signifi-
cant heterogeneity. We should harmonize the minimal
duration, how much should we increase the dose in case
of lack of tolerability and how long should we keep the
treatment before considering it a treatment failure.
Tolerability
Concerning the tolerability profile, most of the re-
sponders preferred beta-blockers but the preferred drugs
were flunarizine, OnabotA, amitriptyline and topiramate.
Some of these drugs have been associated with adverse
events in up to 75 to 82,5% of the patients in the pivotal
trials [13, 14].
Despite the difference of administration, OnabotA was
perceived as well tolerated by a high percentage of neu-
rologists, in line with long-term studies show [18], and it
was selected before GON blockades.
OnabotulinumtoxinA
Spanish experts recommendations for the use of Ona-
botA stated that the first procedure should be performed
according to the PREEMPT paradigm, administering
155 Units and in case of lack of response, dose could be
increased up to 195 Units in the first three procedures
[19]. We found that in certain cases, neurologists admit-
ted to using lesser or higher doses.
To date, some factors have been associated with an in-
creased efficacy to OnabotA in CM: use of higher Ona-
botA dose up to 195 units [15–19], a shorter evolution
of Chronic Migraine, a lesser number of oral preventa-
tives prior to OnabotA using [20]. Despite that Spanish
Guidelines recommend to consider OnabotA after two
therapeutic failures and Spanish Health Care System
covers OnabotA costs all across the country, only 49.5%
of general neurologists surveyed admitted to starting it
after the failure of two preventatives. Similar data in an
Italian survey, showed that only 39,7% of responders said
they commenced OnabotA before the failure of 3 pre-
ventatives [21]. In our sample, it was surprising that one
out of five responders did not increase the dose up to
195 units at the third procedure in case of lack of re-
sponse. Publication of European guidelines [22, 23]
should encourage clinicians to consider it when indi-
cated as it has proven to be an effective therapy also in
real world studies and increase properly the dose in case
of lack of response [20].
Future perspectives
The fact that all currently available preventive drugs have
been developed for other indications may be related to the
presence of adverse events and poor compliance. The ar-
rival of novel specific drugs such as anti-CGRP antibodies
and gepants could dramatically change the clinical picture
[24, 25]. Nevertheless, despite most of the participants
said that the presence of comorbidities was the main fac-
tor in the selection of the therapy; we found that the deci-
sion was correlated most with the perceived efficacy
rather than the tolerability profile.
The panorama will change in the coming years and
some factors will be of striking importance, such as the
availability of the therapies, its efficacy in real world set-
ting and the diffusion among the majority of clinicians.
We support the creation of new European Guidelines
and the harmonization of the National Guidelines ac-
cording to the current literature.
Our study has some limitations. As an online survey,
not all the members of the Headache Study Group
responded to it and the answers might not represent the
opinions of all the Headache Specialists. Among the 51
questions, some of them were subjective and we did not
allowed more than two possible answers.
Also, our results reflect only opinion among Spanish
neurologists, with a public healthcare system different of
those from many other European Countries. Finally, we
did not analysed non-pharmacological therapies or co-
morbidities management, which should be considered
for future studies.
Conclusion
Our study states that the main criterion in the selection
of treatments is the subjective perceived efficacy, topira-
mate being the drug considered as the most effective
and therefore the first choice drug in CM and EMWA.
Despite the availability of many novel therapies, most
of the clinicians employed the classical drugs.
Additional file
Additional file 1: Table S1. First and second choices in chronic
Migraine. Number represent percentage or the total responses. Table S2.
First and second choices in episodic migraine without Aura.
Numberrepresentspercentage of total responses. Table S3. First and
second choices in episodic migraine with Aura. Numbers represents
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percentage of total responses. Table S4. Perception about efficacy of the
different drugs in the treatment of chronic migraine. Numbers represent
percentage of the answers. Table S5. Perception about efficacy of the
different drugs in the treatment of episodic migraine. Numbers represent
percentage of the answers. Table S6. Answers about the drugs
considered as the best tolerated and second best tolerated. (DOCX 68
kb)
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